Beltavac is under clinical development by Probelte Pharma and currently in Phase III for House Dust Mite Allergy. According to GlobalData, Phase III drugs for House Dust Mite Allergy have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Beltavac’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Beltavac overview

Beltavac is under development for the treatment of house dust mite allergy in patients with allergic rhinitis or rhinoconjuntivitis. The vaccine candidate comprises of polymerized allergenic extract from house dust mites. It is administered through subcutaneous route in the form of suspension.

Probelte Pharma overview

Probelte Pharma operate in healthcare sector. Probelte Pharma is headquartered in Murcia, Spain.

For a complete picture of Beltavac’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.